Response to antiretroviral therapy: Improved survival associated with CD4 above 500 cells/μl

AIDS

Volumn 26, Issue 11, 2012, Pages 1393-1398

  Maman, David ^a,b,c,d   Pujades Rodriguez, Mar ^a   Nicholas, Sarala ^a   McGuire, Megan ^a   Szumilin, Elisabeth ^a   Ecochard, René ^a   Etard, Jean François ^a,e  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

antiretroviral therapy; CD4; epidemiology; HIV; mortality; sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AFRICA; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; VIRAL LOAD;

EID: 84863727758     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328352d054     Document Type: Article

References (13)

1. World Health Organisation. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: WHO, UNAIDS, UNICEF; 2010.
2. Etard J-F, Ndiaye I, Thierry-Mieg M, Guèye NFN, Guèye PM, Lanièce I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189. (Pubitemid 43786107)
3. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:2303-2311.
4. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24:563-572.
5. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010 revision. Geneva: World Helth Organisation; 2010.
6. DHHS Panel. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. National Institute of Health: Department of Health and Human Services; (2011). pp. 1-239. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL. pdf. [Accessed 8 March 2011]
7. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Nat Cancer Instit 2010; 102:784-792.
8. Lawn SD, Myer L, Edwards D, Bekker L-G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-1725.
9. Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, et al. Death rates in HIV-positive antiretroviralnaive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376:340-345.
10. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154:509-515.
11. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDSfree HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
12. Hoover DR, Graham NM, Chen B, Taylor JM, Phair J, Zhou SY, Muñoz A. Effect of CD4R cell count measurement variability on staging HIV-1 infection. J Acquir Immune Def Syndr 1992; 5:794-802.
13. Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu C. Measurement error in nonlinear models: a modern perspective. 2nd ed. London, UK: Chapman & Hall; 2006.